Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Valent U S A LLC manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area, which currently includes 1 pending office action. This 1 pending office action defines the current extent of the company's active interactions with the patent office. The limited number of pending actions may reflect a selective filing strategy or a specific phase in the company's biotech IP lifecycle.
The prosecution is currently managed by 1 distinct examiner and 1 distinct art unit. The use of 1 distinct art unit suggests that the company's innovations are classified within a narrow technical field. This arrangement simplifies the administrative tracking of the portfolio, as all current examiner feedback is funneled through the 1 distinct art unit, which can lead to more consistent prosecution outcomes.
PIPIC, ALMA is the busiest examiner for the portfolio, with 1 busiest examiner pending office action currently assigned. This examiner is responsible for the 1 busiest examiner pending office action in the company's active docket. The prosecution path is dependent on the review and response cycle associated with the 1 distinct examiner, allowing for a focused interaction with the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIPIC, ALMA | 1 | 54.6% | +54.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17137985 | BACILLUS AMYLOLIQUEFACIENS AND NEONICOTINOIDS MIXTURES AND METHODS OF USE THEREOF | PIPIC, ALMA | 89d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17137985 | BACILLUS AMYLOLIQUEFACIENS AND NEONICOTINOIDS MIXTURES AND METHODS OF USE THEREOF | PIPIC, ALMA | 1617 | §103 | Final Rejection | 89d overdue | Pending | Dec 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial